Updates are available Correction dated 2022-03-19
Click to view Correction: https://doi.org/10.1245/s10434-022-11601-5
-
Authors
Nessim, Carolyn
Raut, Chandrajit P.
Callegaro, Dario
Barretta, Francesco
Miceli, Rosalba
Fairweather, Mark
Blay, Jean-Yves
Strauss, Dirk
Rutkowski, Piotr
Ahuja, Nita
Gonzalez, Ricardo
Grignani, Giovanni
Quagliuolo, Vittorio
Stoeckle, Eberhard
Lahat, Guy
De Paoli, Antonino
Pillarisetty, Venu G.
Canter, Robert J.
Mullen, John T.
Pennacchioli, Elisabetta
van Houdt, Winan
Swallow, Carol J.
Schrage, Yvonne
Cardona, Kenneth
Fiore, Marco
Gronchi, Alessandro
Bagaria, Sanjay P.
- License Information
-
More Information
Article History
First Online: 20 June 2021
Change Date: 19 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1245/s10434-022-11601-5
Disclosure
: Piotr Rutkowski has received honoraria for lectures and serves on Advisory Boards of Novartis, BMS, MSD, Pierre Fabre, Sanfoi, Merck, Pfizer, and Blueprint Medicines. Nita Ahuja is a consultant for Cepheid and also has grant funding from Van Andel Research Institute–Stand Up to Cancer Epigenetics Dream Team. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by AACR. She is a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation and sits on the Yale New Haven Hospital Board of Trustees; licensed methylation biomarkers to Cepheid (Patent #10167513); shares in Coca-Cola and IBM. Her spouse is an IBM employee and owns a private technology company. Giovanni Grignani has received grants from Bayer, Pharmamar, and Novartis as well as personal fees from Novartis, Bayer, Pharmamar, Lilly, EISAI, Merck, and Tesaro.
